UK: Cas-Cading Events In The IP Battle Over CRISPR Technologies

Last Updated: 29 March 2017
Article by Kevin Tipping

On 15 February the USPTO announced its long-awaited decision regarding the CRISPR patent interference proceedings between the University of California Berkley (UCB) and the Broad Institute of MIT. The decision closes the door on an important chapter of the increasingly bitter dispute over who owns the fundamental IP protecting CRISPR technologies. In short, despite filing after UCB, the Broad's US patents have been held not to interfere with UCB's patent application, mainly because the judiciary panel believed that the implementation of the CRISPR system into eukaryotic cells did involve an inventive step. It is generally accepted that the outcome will not prevent the UCB from securing patent protection themselves, and thus the decision does not really address the central issue of who ultimately controls the right to exploit the technology in the US.

Nevertheless, the buzz surrounding the outcome marks the decision as another important landmark in the CRISPR story. What follows is an explanation of why CRISPR is considered to be such a revolutionary innovation and how the two sides will continue to push for global protection regardless of the USPTO's decision.

What is CRISPR?

In its native guise, the CRISPR/Cas system provides inheritable bacterial immunity to protect microbes against invading pathogens. It works by first recognising then cutting and pasting short segments of foreign DNA into a particular locus of its own genome. The corresponding RNA transcribed and processed from these short DNAs, known as CRISPRs, combine with the Cas protein to constantly survey the host for the DNA of the foreign pathogen. Once encountered, Cas compromises the invading species by cleaving the foreign DNA at the sequence complementary to the RNA, thus sparing the microbe from a potentially devastating infection.

CRISPR was first reported in the scientific literature in the late 1980s, and for the next two decades research in the area was confined to a relatively small but dedicated community of scientists. That all changed in August 2012, when a group from University of California Berkley (UCB) reported the revolutionary finding that CRISPR/Cas9 could be engineered to cleave targeted genetic sequences (Jinek et al, Science).

Of course, genetic engineering is not a novel idea, but gene editing techniques that pre-date CRISPR are cumbersome, and typically rely on the engineering of protein interfaces for the specific recognition and cleavage of target DNA sites. Such projects can take months, even years, and considerable expense to achieve, and there is no guarantee of success.

The beauty of CRISPR/Cas lies in its simple approach to gene editing: recognition and cleavage of the target DNA using a complimentary strand of RNA. Thus, a simple, relatively inexpensive molecule can be rapidly synthesized to target and cleave DNA sequences with high specificity. Moreover, CRISPR can be used to edit multiple genes simultaneously and can be modified for use in a variety of organisms. Unsurprisingly, therefore, the range of applications that can benefit from CRISPR/Cas is limited only by the imagination. Despite its relative infancy, CRISPR/Cas has already rapidly advanced research areas as diverse as human therapeutics, disease modelling, and agricultural science.

Opposing strategies for global protection

The excitement and potential of CRISPR is reflected in the world of IP. As of September 2016, more than 860 patent families relating to CRISPR technologies had been filed. The explosion of CRISPR-related filings illustrates why owning the foundational rights to CRISPR is such a lucrative commodity.

First and foremost, it is unclear what impact, if any, the USPTO's decision will have outside the US, particularly in jurisdictions such as Europe, which operates the first to file rule. Setting aside the decision for a moment, it is interesting to observe the different strategies each side has taken for protecting CRISPR in Europe and the UK.

Firstly, the European arm of the Broad portfolio (Figure 1) highlights a particularly aggressive strategy for securing patent protection. This has so far involved the filing of multiple applications and frequently requested expedited review. It is interesting to speculate as to the motive behind this approach. Perhaps the decision was influenced by Broad having to play catch-up by virtue of their later filing date. Nevertheless, the strategy could be considered a success, having resulted in nine granted EP patents and at least eight pending applications sharing up to 12 priority dates, the earliest of which is 12 December 2012.


Figure 1 The EP Broad portfolio of applications sharing the 12 December 2012 priority date. Blue lines indicate the priority year of individual PCTs, black represents the international phase and red the entry into the regional phase. Green indicates the granted EP patents, with numbers identifying the individual applications.

By contrast, UCB has a single application under examination at the EPO with an earliest priority date of 25 May 2012. The UCB team has also managed to acquire a granted ex-PCT GB patent covering CRISPR/Cas, as well as three branch-off German utility models (Figure 2). Strategically, the GB patent could become particularly important for safe-guarding protection in the UK in the event of the EP application failing to grant.


Figure 2 The UCB portfolio. This illustrates the contrasting approach UCB has taken to securing protection.

Looking more closely at the prosecution of the UCB EP application, it will come as no surprise that multiple third parties have filed observations attacking the patentability of the application. Although the observations are extensive, the main issue focusses on the entitlement of the UCB application to the earliest priority date of May 2012 (Figure 3 – P1). At least initially, several parties successfully argued that P1 did not provide an enabling disclosure by failing to explicitly disclose an essential feature of the CRISPR system. As a consequence, the earliest priority date shifted to October 2012, which although is still before the earliest priority date of the Broad patents, is after the publication of the Jinek paper, thus making UCB's own publication a novelty destroying disclosure (Figure 3a). Nevertheless, the most recent examination report issued by the EPO suggests that UCB has managed to successfully restore their original priority claim, raising hopes that the application will soon proceed to grant.


Figure 3 The UCB priority issue.

What next?

So, what with the recent outcome of the US interference proceedings and the impending grant of the UCB EP application, the dispute surrounding the ownership of CRISPR IP is gaining traction. However there still remains a long road ahead to establishing with any certainty who, if either, of the Broad or UCB, exclusively owns the foundational rights to CRISPR IP in any jurisdiction. One thing that is for sure is that the continuing investment and excitement surrounding CRISPR/Cas means there will be many observers keeping a keen eye on how the proceedings pan out, particularly prospective licensees, who must be looking forward to navigating the complex CRISPR licensing landscape to ensure they can properly work their inventions.


Jinek et al. (2012) Science, 337, 816.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.